Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil

• DOI: 10.3389/fphar.2024.1414244
• Publication Date: 2025-01-10T08:31:47Z
• Authors: Pamela Santos Aze...; Isabella Zuppo Laper; Deborah Marta do ...; Adriano de Paula ...; Marina Morgado Ga...; Isabela Cristina ...; Wallace Mateus Prata; Mariângela Leal C...; Juliana Álvares-T...; Francisco de Assi...; Augusto Afonso Gu...
• Keywords: Follicular lymphoma; Systemic therapy

Follicular lymphoma (FL) is a common type of non-Hodgkin that incurable but often follows an indolent course. While survival improving thanks to advances in diagnosis, supportive care, and new therapies, understanding outcomes their impact on overall still limited. There are few studies FL Brazil, so this study aims evaluate the patient's profile, morbidity mortality treated by Brazilian national health service (SUS) risk factors associated with treatment failure. This nationwide 16 years cohort patients underwent chemotherapy SUS (2000-2015). The Kaplan-Meier method was used estimate until failure, Cox proportional hazards model factors. included 10,009 rates were 73.3%, 45.3%, 30.7% for first, fifth 10th year respectively. median approximately 4.1 years. most regimen CHOP (13%), followed CVP (9.7%) R-CHOP (3.3%). Four hundred ninety-eight (4.9%) rituximab-containing regimens. Univariate analysis indicated worse male patients, those over 65 age, clinical stage III or IV using non-rituximab-containing technology performance assessment related oncology schemes suggests rituximab-based regimens has shown best probability (0.52 CI 0.39-0.69) 78 months follow up HR 1.5 times better than other (HR 0.67; 0.55-0.81). In light substantial advancements achieved SUS, there need CONITEC expedite decision-making processes order enhance access drugs. should be done while upholding standards. Timely integration sufficient funding services have potential save lives, especially when compared treatments available within at time.